Clinical trials: Esophageal Neoplasm
Gastric Cancer
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
This randomized, open-label, multicenter, international Phase IIIb study will compare the efficacy and safety of two Herceptin dosing regimens in combination with cisplatin/capecitabine chemotherapy in participants with…
- Trial name
- HELOISE (NCT01450696)
- Testing
- Capecitabine, Cisplatin, Herceptin
- Where
- 117 sites in United States, Australia and 23 more
- Volunteers
- 296 people
- Sponsor
- Hoffmann-La Roche
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)
This phase II MATCH treatment trial identifies the effects of ado-trastuzumab emtansine in patients whose cancer has a genetic change called HER2 amplification.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439110
- Testing
- Trastuzumab Emtansine
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Non Small Cell Lung Cancer
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
The purpose of the study is to estimate the rate of response for patients with ovarian, non-small cell lung, prostate, colorectal, gastroesophageal, and head and neck cancers who are administered LY2523355.
- Conditions
- Ovarian Cancer, Non Small Cell Lung Cancer, Prostate Cancer, Colorectal Cancer
- Trial name
- NCT01059643
- Testing
- LY2523355, pegfilgrastim
- Where
- 18 sites in United States
- Volunteers
- 103 people
- Sponsor
- Eli Lilly and Company
Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
This randomized phase II trial studies how well paclitaxel with or without cixutumumab works in treating patients with esophageal cancer or gastroesophageal junction cancer that has spread to other places in the body…
- Conditions
- Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Adenocarcinoma
- Trial name
- NCT01142388
- Testing
- Cixutumumab, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 232 sites in United States
- Volunteers
- 94 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Squamous Cell, Adenocarcinoma of the Esophagus and Gastric Cardia
Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia
The purpose of this randomized study is to clarify if neoadjuvant radiochemotherapy gives a higher degree of complete histological response than neoadjuvant chemotherapy before surgery in patients undergoing treatment for cancer…
- Trial name
- NeoRes (NCT01362127)
- Testing
- Chemotherapy, Radiochemotherapy
- Where
- Sweden
- Volunteers
- 181 people
- Sponsor
- Karolinska University Hospital
Urinary Bladder Cancer, Melanoma
MAGE-A4ᶜ¹º³²T for Multi-Tumor
This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung…
- Conditions
- Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer
- Trial name
- NCT03132922
- Testing
- Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
- Where
- 11 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- USWM CT, LLC
Carcinoma, Squamous Cell, Oral Cancer
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
Participants in this study have a type of cancer called squamous cell carcinoma of the head and neck (SCCHN). Their SCCHN has spread around the area where the cancer first started. This is called locally-advanced SCCHN.
- Conditions
- Carcinoma, Squamous Cell, Oral Cancer, Oropharynx Cancer, Larynx Cancer
- Trial name
- NCT03174275
- Testing
- Durvalumab, Carboplatin, Nab-paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Esophageal Neoplasms, Stomach Neoplasms
Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma
The purpose of this study is to evaluate the progression free survival of capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin) in previously untreated metastatic esophagogastric adenocarcinomas.
- Conditions
- Esophageal Neoplasms, Stomach Neoplasms, Neoplasm Metastasis
- Trial name
- XAGastric (NCT00447330)
- Testing
- capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Duke University
ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Radiofrequency Ablation for Patients With Esophageal Squamous Cell Neoplasia
Patients with MGIN, HGIN or flat-type early SCCA of the esophagus will be treated on 3 month intervals with Radiofrequency Ablation (RFA) until complete eradication (CR: no MGIN or worse in the biopsies) will be achieved.
- Trial name
- NCT02047305
- Testing
- Radiofrequency Ablation
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Covidien, GI Solutions
Solid Tumors, ER/PR Positive Breast Cancer
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
This is a Phase I study to understand the biodistribution of MM-398 and to determine the feasibility of using Ferumoxytol as a tumor imaging agent.
- Conditions
- Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis
- Trial name
- NCT01770353
- Testing
- Ferumoxytol, MM-398
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- Ipsen
Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).
- Conditions
- Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma
- Trial name
- NCT04068896
- Testing
- NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane
- Where
- 20 sites in United States
- Volunteers
- 89 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Esophageal Cancer, Gastric Cancer
Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer
The purpose of this study is to find out what effects, good and/or bad, pembrolizumab in combination with trastuzumab and chemotherapy, has on the patients' esophagogastric cancer.
- Trial name
- NCT02954536
- Testing
- pembrolizumab, trastuzumab, capecitabine
- Where
- 8 sites in United States
- Volunteers
- 37 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gastric Cancer, Gastroesophageal Junction Cancer
Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer
The main purpose of this study is to compare how long patients with gastric or gastroesophageal junction cancer live after receiving nivolumab and ipilimumab or nivolumab and chemotherapy compared with patients receiving…
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
- Trial name
- CheckMate649 (NCT02872116)
- Testing
- Nivolumab, Ipilimumab, Oxaliplatin
- Where
- 179 sites in United States, Argentina and 27 more
- Volunteers
- 2,031 people
- Sponsor
- Bristol-Myers Squibb
Dysphagia, Head and Neck Cancer
Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Conditions
- Dysphagia, Head and Neck Cancer, Mucositis, Xerostomia
- Trial name
- NCT00503776
- Testing
- exercise intervention, amifostine trihydrate, therapeutic dietary intervention
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Esophageal Cancer
Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery
The purpose of this study is to test the safety and effectiveness of erlotinib and FOLFOX in patients with esophageal or gastro-esophageal cancer that cannot be removed by surgery.
- Trial name
- NCT00539617
- Testing
- Erlotinib, 5-fluorouracil, Leucovorin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Francisco
Morbid Obesity, Hernia
Minimally Invasive Surgery (MIS) Database for the Purpose of Research
The Minimally Invasive Surgery Team (MIST) are establishing a separate research database to find out more about patient's undergoing minimally invasive surgery (laparoscopic , open and robot assisted) procedures at UCSD.
- Conditions
- Morbid Obesity, Hernia, Colorectal Cancer, Laparoscopy
- Trial name
- NCT00535990
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Barrett Esophagus, Gastroesophageal Reflux
Assessment of Zegerid on Esophageal pH in Patients With Barrett's Esophagus
The purpose of this research study is to assess how safe, effective (how well it works), and tolerable (to put up with) the drug Zegerid is in reducing reflux episodes in patients who have both gastroesophageal reflux disease…
- Trial name
- NCT01129778
- Testing
- Zegerid (proton pump inhibitor), Bravo pH monitoring
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Stanford University
Gastro-Oesophageal Cancer
RegoNivo vs Standard of Care Chemotherapy in AGOC
To determine if the regorafenib and nivolumab combination (RegoNivo) improves overall survival compared with current standard chemotherapy options in refractory AGOC.
- Trial name
- INTEGRATEIIb (NCT04879368)
- Testing
- Regorafenib, Nivolumab, Docetaxel
- Where
- 94 sites in United States, Australia and 7 more
- Volunteers
- 462 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Esophageal Fistula, Esophageal Neoplasms
Removal of the Evolution® Esophageal Stent - Fully Covered
The CLARITY study is a clinical trial approved by US FDA to study the removal of the Evolution® Esophageal Stent-Fully Covered in malignant and benign indications.
- Conditions
- Esophageal Fistula, Esophageal Neoplasms, Esophageal Perforation, Esophageal Stenosis
- Trial name
- CLARITY (NCT01900691)
- Testing
- Evolution® Esophageal Stent - Fully Covered
- Where
- 11 sites in United States
- Volunteers
- 130 people
- Sponsor
- Cook Group Incorporated
Esophageal Cancer, Non-small Cell Lung Cancer
Early Prediction of Pathology Response of Chemoradiotherapy With FLT PET
The goal of this research study is to learn if a new type of PET scan (18F-FLT) can help to better detect changes of tumor growth rate (or how active) in esophagus cancer and lung cancer Researchers will study at what time during…
- Trial name
- NCT01065818
- Testing
- Fluoro-L-Thymidine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Columbia University